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The infiltrative nature of Glioblastoma (GBM), the most aggressive primary brain tumor,
critically prevents complete surgical resection and masks tumor cells behind the blood brain
barrier reducing the efficacy of systemic treatment. Here, we use a genome-wide interference
screen to determine invasion-essential genes and identify the AN1/A20 zinc finger domain
containing protein 3 (ZFAND3) as a crucial driver of GBM invasion. Using patient-derived
cellular models, we show that loss of ZFAND3 hampers the invasive capacity of GBM,
whereas ZFAND3 overexpression increases motility in cells that were initially not invasive. At
the mechanistic level, we find that ZFAND3 activity requires nuclear localization and integral
zinc-finger domains. Our findings indicate that ZFAND3 acts within a nuclear protein com-
plex to activate gene transcription and regulates the promoter of invasion-related genes such
as COL6A2, FN1, and NRCAM. Further investigation in ZFAND3 function in GBM and other
invasive cancers is warranted.
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Cancer cell invasion and ensuing metastasis are a leadingcause of death. Malignant tumors of the brain, includingGlioblastoma (GBM), are characterized by a high invasive
capacity leading to a spread throughout the brain parenchyma1, a
growth pattern which is largely accountable for the current
therapeutic failure and poor patient outcome. Invasive cells that
migrate away from the tumor core escape surgical resection, are
partially sheltered from radio- and chemotherapy and are not
detected by standard imaging techniques. Furthermore it was
recently shown that glial tumors form multicellular networks
through ultra-long membrane protrusions, so-called tumor
microtubes, that facilitate brain invasion and contribute to
treatment resistance2,3.
Due to the specific structure of the adult brain, GBM invasion
differs from vascular or lymphathic pathways classically associated
with peripheral metastatic cancer. GBM cells insinuate themselves
in the interstitial space of the neural tissue or migrate along blood
vessels and white matter tracts, relying on basal membranes and
extracellular matrix (ECM) components4. Although significant
efforts were carried out to elucidate the mechanisms underlying
GBM cell invasion (e.g., cytoskeleton remodeling, secretion of
proteases, intracellular signaling)5, therapeutic approaches tar-
geting GBM invasion have not heralded any benefit so far and
novel targets regulating the invasive process are actively being
pursued6–8.
RNA interference screens are powerful tools to uncover gene
function and their contribution to specific cellular phenotypes9.
Such approaches allowed e.g., the identification of genes involved
in cell migration and invasion in various cancer models10,11
including GBM12. Here, we applied genome-wide RNA inter-
ference in GBM and identified AN1-Type Zinc Finger protein 3
(ZFAND3) as a key regulator of GBM cell invasion. Zinc finger
(ZF) proteins are involved in nucleic acid recognition, tran-
scriptional activation, protein folding and assembly, however the
function of ZFAND3 remains unknown. ZFAND3 (also known as
testis expressed sequence 27, Tex27) was initially characterized
during mouse sperm maturation13,14 and was associated with
susceptibility for development of type 2 diabetes in humans15,16.
We find that ZFAND3 strongly potentiates invasiveness of GBM
patient-derived cells in vitro, ex vivo and in vivo. We show that
nuclear ZFAND3 expression is increased in the infiltrative com-
partment in GBM patient biopsies and that nuclear localization is
essential for ZFAND3 activity. Finally we identify ZFAND3 as a
transcription factor that regulates expression of adhesion and
invasion-related genes.
Results
RNA interference screen identifies ZFAND3 as a candidate
gene involved in GBM invasion. Although GBMs in patients are
invariably invasive, not all patient-derived GBM cells display the
same invasion capacity. Inter-patient differences can be observed
when patient-derived GBM stem-like cells (GSCs) are implanted
into the mouse brain: Non-invasive (NI) cells grow as circum-
scribed tumors displaying aberrant blood vessels and necrosis;
low invasive (LI) cells partially invade into the cortex and traverse
the corpus callosum to the contralateral hemisphere and highly
invasive cells (HI) completely colonize the brain parenchyma of
both hemispheres (Fig. 1a, additional examples on Supplementary
Fig. 1a, b). We have previously described similar histological
phenotypes with differential invasive potential in GBM patient-
derived orthotopic xenografts based on organotypic tumor
spheroids17. Interestingly the distinct invasive behavior of GSCs
could be recapitulated in vitro, e.g., using 3D-Boyden chamber
assays (Fig. 1b, c, Supplementary Fig. 1a, b) or sphere sprouting
assays (Fig. 1d, e). We further confirmed the differential invasive
phenotypes in ex vivo invasion assays in organotypic brain slice
cultures, which allowed to determine differences in single cell
velocity (Fig. 1f–i). The invasion capacity was correlated to the
expression of some (CDH2, MMP2, SNAI1, ZEB1) but not all
known invasion markers in vitro and in vivo (Supplementary
Fig. 1c–h), but did not correlate to transcriptional GBM subtypes
(proneural, mesenchymal, classical) as defined by Wang et al.18
(Supplementary Fig. 1i). Taken together these data indicate that
patient-derived GSCs faithfully reflect the heterogeneity and
invasion capacity of GBM in vivo, ex vivo and in vitro.
Using highly invasive (HI) GBM GSCs, we performed a
genome-wide loss-of-function shRNA screen to uncover novel
key drivers of GBM invasion. Invasion-defective and invasion-
competent cells were specifically isolated using the Boyden
chamber assay (Fig. 2a). In highly aneuploid cancer cells, such as
GBM GSCs, RNA interference may be more reliable then CRISPR
based knockout screens, because the transcripts rather than the
DNA are targeted9. Focusing on the invasion-defective cells,
barcoded shRNAs were sequenced and a stringent bioinformatic
analysis pipeline was applied by combining four of the most
common analysis methods: RSA19, RIGER20, MAGeCK21,22, and
HiTSelect23 (Supplementary Fig. 2a, b). Only the gene candidates
in common between all four methods were selected, resulting in a
set of 17 invasion-essential candidate genes within the 2% top hits
(Fig. 2b). This included Colony stimulating factor 1 (CSF1), a
known cytokine involved in invasion and metastasis. To further
reduce the number of gene candidates of interest, we analysed the
expression of the 17 genes in NI, LI, and HI cells in vitro and
when grown as xenografts in vivo. Compared to other candidate
genes, the AN1-Type Zinc Finger protein 3 (ZFAND3) gene
showed higher expression in HI cells compared to NI and LI cells,
in vitro as well as in vivo, and corresponding knockdown clones
were enriched in the analysis (Supplementary Fig. 2b–d), we
therefore focused on ZFAND3 for further analysis. Quantitative
real time PCR (qPCR) confirmed a higher expression of ZFAND3
in HI cells, compared to LI and NI (Fig. 2c). Immunohistochem-
istry of corresponding GBM xenografts in the mouse brain
showed more ZFAND3 positive cells in HI tumors in comparison
to LI tumors (Fig. 2d). Analysis of TCGA data via the GlioVis
platform24 revealed strong ZFAND3 expression in all classes of
diffuse glioma compared to nontumor controls (Supplementary
Fig. 2e), in line with the high invasive potential of these tumors.
There was no correlation with transcriptional GBM subtypes
(Supplementary Fig. 2f). Pan-tumor studies based on TCGA and
GTEx databases (via GEPIA platform)25,26 also highlighted
increased ZFAND3 expression in diverse cancers compared to
control tissue, in particular in pancreatic adenocarcinoma and
melanoma (Supplementary Fig. 2g). Next we analysed ZFAND3
protein expression in 21 fresh GBM patient biopsies. ZFAND3
protein was detected in the majority of GBM (17/21) and
throughout different tumor compartments, including central,
intermediate and peripheral areas (Fig. 2e). By immunofluores-
cence, we found that ZFAND3 was present in the cytoplasm and
the nucleus of GBM cells (identified by P53 staining) and we
analysed the fraction of ZFAND3 positive tumor cells based on
subcellular localization (Fig. 2f and Supplementary Fig. 3a, b).
The fraction of positive cells was similar throughout different
tumor compartments, both for cytoplasmic and nuclear staining
(Supplementary Fig. 3c, d). However, in contrast to cytoplasmic
ZFAND3 staining (Fig. 2g), we found that both the staining
intensity and the ratio of nuclear/cytoplasmic ZFAND3 staining
were increased in peripheral tumor cells compared to central
cells, indicating that the relative fraction of tumor cells with
nuclear ZFAND3 is higher in the tumor periphery, and that
nuclear ZFAND3 is expressed to a higher extent in these cells
(Fig. 2h, i). Since ZFAND3 appeared also in nontumor cells, we
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Fig. 1 Patient-derived GBM stem-like cells (GSCs) display different invasion phenotypes in vivo, which are recapitulated in in vitro and ex vivo assays.
a Early, intermediate and late time point of different GSC orthotopic xenografts in mice displaying non invasive (NI), low invasive (LI) and highly invasive (HI,
HI-2) phenotypes. Respective tumor development times were 5 weeks (NI), 8 weeks (LI) and 25 weeks (HI, HI-2). Anti-human vimentin staining was used
to visualize tumor cells (Scale bars= 100 µm and 1000 µm for overview). (n= 2 mice for each tumor and time point with n= 3-4 sections per mouse). b In
vitro Boyden Chamber invasion assay, displaying the relative number of invaded cells (n= 3). c Representative pictures of in vitro Boyden chamber invasion
assay reflecting the different invasion phenotypes. Scale bar 100 µm. d Quantification of invasion of GSCs in 3D sprouting assay (n= 3). e Representative
pictures of sprouting assay of different GFP-positive GSCs (n= 3) (Scale bar= 1000 µm). GFP: Green fluorescent protein. f Quantification of increase of
colonized area of GSCs in ex vivo brain slice cultures, 9 days after tumor implantation (n= 10). g Representative pictures of GSCs in ex vivo brain slice
cultures at day 0, 4, and 9 (Scale bar= 1000 µm). h Displacement of GSCs injected into ex vivo brain slice cultures (n= 10). i Velocity of GSCs in ex vivo
brain slice cultures. Results of (b, d, f are i) displayed as average ± SEM and were analyzed with one-way ANOVA. **pvalue < 0.01, ****pvalue < 0.0001.
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performed colabeling for Iba1 (microglia marker) and NeuN
(neuronal marker). We observed some colocalization with Iba1,
but not with NeuN, both in clinical samples (Supplementary
Fig. 3e) and in xenografts (Supplementary Fig. 3f), indicating that
ZFAND3 is expressed by a subpopulation of microglial cells. The
majority of staining was found in the tumor area rather than in
the neuropil (Supplementary Fig. 3f lower panel). In conclusion,
we identified ZFAND3 as an invasion-related gene that displays
increased nuclear expression in the infiltrative tumor compart-
ment of clinical GBM specimen.
ZFAND3 knockdown impairs GBM cell invasion in vitro,
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shRNA-mediated knockdown (KD) of ZFAND3 was performed
in two highly invasive GSCs (HI and HI-2). Efficient KD with two
different shRNAs was achieved at RNA and protein level (Fig. 3a,
b and Supplementary Fig. 4a–e). Similar to patient samples,
endogenous ZFAND3 protein displayed cytoplasmic and nuclear
localization, while KD cells only retained minor cytoplasmic
staining (Fig. 3c). ZFAND3 KD had no significant impact on cell
proliferation (Fig. 3d). Using Boyden chamber assays on the same
cells, ZFAND3 KD significantly reduced invasion compared to
shCtrl in HI cells (Fig. 3e, f). This was confirmed in the HI-2 cell
line (Supplementary Fig. 4a–e).
To better imitate invasion in a brain microenvironment, we
implanted GBM HI cells into ex vivo brain slices. In ZFAND3 KD
cells the area of colonization of the brain slice was decreased in
contrast to shCtrl (Fig. 3g, h) and cellular velocity, as determined
by single cell tracking, was reduced accordingly (Fig. 3i, j). Finally,
we evaluated the invasion potential of ZFAND3 KD cell in vivo:
eight weeks after intracranial tumor implantation, the mice were
sacrified and cell invasion to the contralateral hemisphere was
quantified. We found significantly less cells in ZFAND3 KD
tumors compared to control (Fig. 3k, l and Supplementary
Fig. 4j). Taken together these data validate the result of the screen
and indicate that loss of ZFAND3 strongly impairs GBM cell
invasion in vitro, ex vivo and in vivo.
Expression of ZFAND3 confers invasion potential to non-
invasive patient-derived GBM cells. Given that ZFAND3
downregulation considerably decreased the invasion potential of
invasive GSCs, we asked if ZFAND3 overexpression was able to
bestow invasion capacity to non-invasive (NI) GSCs. We there-
fore expressed ZFAND3 in NI GSCs, as shown by qPCR (Fig. 4a)
and western blot analysis (Fig. 4b). Upon overexpression,
ZFAND3 protein mostly accumulated in the nucleus (Fig. 4c) and
did not affect proliferation of the cells (Fig. 4d). Instead we found
that ZFAND3 increased invasion in vitro (Fig. 4e, f) and ex vivo
in brain slice cultures. ZFAND3 expressing cells colonized a
larger area (Fig. 4g, h) and displayed higher velocity (Fig. 4i, j).
Upon transplantation in the mouse brain, ZFAND3 expressing
tumors lost the circumscribed growth pattern of control NI cells
(Fig. 4k and Supplementary Fig. 4k). The number of cells
escaping the tumor mass was significantly increased for ZFAND3
expressing cells, compared to controls (Fig. 4l). These data indi-
cate that ZFAND3 expression confers invasion potential to GBM
cells that were initially not invasive.
Nuclear localization of ZFAND3 is required for GBM cell
invasion. ZFAND3 contains two ZF domains, a N-terminal A20
domain and a C-terminal AN1 domain separated by a linker
region (Fig. 5a). As we found ZFAND3 immunostaining in the
nucleus and nuclear localization was increased in the infiltrative
tumor compartment, we asked whether nuclear localization was
needed for ZFAND3 activity. A ZFAND3 construct with a
mutated nuclear localization signal (NLS) (ZFAND3-mutNLS)
was expressed in NI cells (Fig. 5a–c and Supplementary
Fig. 5a–c). This resulted in ZFAND3 accumulation in the cyto-
plasm (Fig. 5d) and prevented ZFAND3-induced invasion
(Fig. 5f, g). The addition of a second NLS sequence to the mutant
construct rescued both nuclear localisation and the invasion
phenotype (Fig. 5a–g), indicating that ZFAND3 was active in the
nucleus. No impact on proliferation was observed (Fig. 5e). In
summary, these data demonstrate that nuclear localization is
required for ZFAND3-induced invasion.
Deletion of zinc-finger domains leads to loss of invasion phe-
notype. In an attempt to further uncover the molecular basis of
its activity, we generated ZFAND3 mutants with deletion of
individual or both ZF domains (ZFAND3-Δ1, Δ2, and Δ1Δ2)
(Fig. 5a and Supplementary Fig. 5a), and expressed them in NI
GSCs (Fig. 5h, i). None of the variants exhibited proliferation
defects (Fig. 5j). In contrast to full length ZFAND3, no increase in
invasion was observed in cells expressing ZFAND3-Δ1,
ZFAND3-Δ2 or ZFAND3-Δ1Δ2 (Fig. 5k, l), suggesting that both
ZF domains are required for induction of invasion. Of note, while
the double deletion construct accumulated in the cytoplasm,
ZFAND3-Δ1 and ZFAND3-Δ2 correctly translocated to the
nucleus (Fig. 5m). To further pinpoint the active residues, we
generated point mutations in putative zinc-complexing amino
acids (M1, M2, and M1-M2) (Supplementary Fig. 5a). These
constructs retained nuclear localization, but also full activity with
regard to the invasive phenotype (Supplementary Fig. 5b–g). In
conclusion, although the exact residues conferring nuclear
ZFAND3 activity remain elusive, our data hint to the need of
both ZF domains to trigger invasion in GBM cells, suggesting that
ZFAND3 may act as a transcriptional regulator.
ZFAND3 is involved in transcriptional regulation of invasion-
related genes. To address whether ZFAND3 correlates with the
expression of genes involved in migration and epithelial-
mesenchymal transition, we analysed expression of CDH2 (coding
for N-cadherin), MMP2, SNAI2 and ZEB1 in GSCs with various
ZFAND3 expression levels. Surprisingly, the modulation of ZFAND3
expression (KD or overexpression) or function (mutation con-
structs) did not affect expression of these genes (Supplementary
Fig. 6). We therefore performed RNA sequencing on shCtrl,
shZFAND3-1 and shZFAND3-2 HI cells to gain broader insight into
the transcriptional landscape upon ZFAND3 knockdown. Among
the differentially expressed genes (DEGs), 58 genes were significantly
downregulated in both shZFAND3-1 and shZFAND3-2 versus
Fig. 2 Expression of ZFAND3 is associated with GBM cell invasion. a Set up of genome-wide shRNA pooled screen selecting for invasion-defective and
invasion-competent cells in ECM-collagen coated transwell chambers. b Loss-of-function screen focused on shRNAs significantly enriched in invasion-
defective cells. Results were analysed with RSA, RIGER, MAGeCK and HitSelect methods, identifying 17 genes as the top 2% common hits. c qPCR showed
higher ZFAND3 expression in highly invasive GSCs (HI, HI-2) compared to non invasive (NI) (n= 3; p= 0.007) and low invasive (LI) cells (n= 3
biologically independent samples). Results are displayed as average ± SEM and were anlysed with one-way ANOVA. *pvalue < 0.1. d IHC for ZFAND3 in
intracranial GBM xenografts in mice generated from respected patient-derived GSCs (NI, LI HI) (Scale bars= 50 µm, hematoxylin counterstaining). e IHC
revealed ZFAND3 protein in GBM patient biopsies in the tumor core (central), intermediate area (intermediate) and tumor margin with diffuse infiltration
(periphery) (Scale bars= 100 µm). Representative images are shown (n= 21). f Triple immunofluorescence identified ZFAND3 staining in cytoplasm and
nucleus of positive tumor cells: ZFAND3 (red), P53 (green) and DAPI (blue) (Scale bar upper row= 50 µm, lower row= 15 µm). (n= 17 different partient
samples). Mean intensity of cytoplasmic (g) and nuclear (h) ZFAND3+ tumor cells in central, intermediate, and peripheral tumor areas, the latter being
increased in the periphery (n= 17). Data were analyzed as matched data with one-way ANOVA and Tukey´s multiple comparison test. (p= 0.009) i Ratio
of nuclear/cytoplasmic ZFAND3 staining is increased in the periphery compared to the central tumor area (n= 17 patient samples). Data were analysed as
matched data with Kruskal–Wallis test and Dunn’s multiple comparison test (p= 0.012). *pvalue < 0.05, **pvalue < 0.01.
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shCtrl HI cells (FDR < 0.05, logFC <−0.5) (Fig. 6a, b, Supplemen-
tary Fig. 7a, b). Gene ontology analysis associated these DEGs with
adhesion and motility-related pathways, such as migration, integrin
complex, ECM and cell adhesion (Fig. 6c). Among these DEGs, we
selected genes reportedly linked to GBM cell invasion including
COL6A2 (alpha-2 subunit of type VI collagen), EGFR (epidermal
growth factor receptor), FN1 (fibronectin 1), NRCAM (neuronal cell
adhesion molecule) and NRP1 (neuropilin 1), and confirmed their
downregulation upon ZFAND3 KD (Fig. 6d–h), thus supporting a
































































































































































































Fig. 3 Knockdown of ZFAND3 decreases invasion capacity of highly-invasive GBM cells. a qPCR confirming knockdown (KD) of ZFAND3 in highly
invasive GCSs (HI) using two ZFAND3 shRNAs (n≥ 3 biologically independent samples). Results are displayed as average ± SEM and were analysed with
one-way ANOVA. b, c Decrease of ZFAND3 protein in ZFAND3 KD by western blot (n= 3) and IF staining (red: ZFAND3, blue: DAPI. Scale bars= 10 µm)
(n= 2). In analogy to patient samples, ZFAND3 protein is present in the nucleus and cytoplasm. d Growth curves of control and ZFAND3 KD cells show no
defect in cell proliferation (n= 3 biologically independent experiments). e, f Boyden chamber invasion assay showing reduced invasion in ZFAND3 KD cells
compared to control (n= 4 biologically independent experiments) (Scale bar= 100 µm). Results are displayed as average ± SEM and were analysed with
one-way ANOVA. g, h ZFAND3 KD cells implanted in ex vivo brain slice cultures showed reduced colonization compared to control cells, 9 days after
tumor implantation (n= 10 biologically independent samples) (Scale bar= 1000 µm). Results are displayed as average ± SEM and were analysed with a
two-way ANOVA. i, j Visualization and quantification of single cell displacement of ZFAND3 KD cells in ex vivo brain slice cultures showing reduced
velocity compared to control (n= 15 cells over 10 biologically independent samples). Results are displayed as average ± SEM and were analysed with one-
way ANOVA. k, l Upon intracranial implantation (n= 3 biologically independent animals), ZFAND3 KD cell invasion toward the contralateral hemisphere
was decreased compared to control tumors. GBM xenografts were analyzed at 2 months post-surgery (3 sections per mouse) (Scale bar= 100 µm).
Results are displayed as average ± SEM and were analysed with an unpaired, two-sided t test. *pvalue < 0.05, **pvalue < 0.01, ***pvalue < 0.001, ****pvalue <
0.0001.
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Fig. 4 Overexpression of ZFAND3 in non-invasive GBM cells confers invasion potential. ZFAND3 overexpression in non-invasive GSCs (NI) (n= 4
biologically independent samples) confirmed by qPCR (a), Western blot (n= 3) (b) and with IF staining (c) (red: ZFAND3, blue: DAPI. Scale bars= 10 µm).
d ZFAND3-overexpression did not affect cell proliferation (n= 3 biologically independent experiments). e, f Boyden chamber invasion assay indicating
increased invasion potential in ZFAND3-overexpressing cells (n= 6 biologically independent experiments) (Scale bar = 100 µm). g, h ZFAND3-
overexpressing cells implanted in ex vivo brain slice cultures showed augmented colonization compared to control cells, 9 days after tumor implantation
(n= 10 biologically independent samples) (Scale bar = 1000 µm). i Velocity of ZFAND3-overexpressing cells in ex vivo brain slice cultures was improved
compared to control cells (n= 10, p < 0.0001). j Visualization of single cell displacement for control and ZFAND3-overexpressing cells in ex vivo brain slice
cultures (n= 15 cells over 10 biologically independent samples). k, l Upon orthotopic xenografting in mice (n= 3), an increased number of ZFAND3-
overexpressing cells invaded out of the tumor border into the surrounding tissue, compared to control cells (analysis done at 4 weeks after implantation)
(3 sections per mouse) (Scale bar = 100 µm). Results of (a, e, g, j, l) are displayed as average ± SEM, results of (a, e, j, and l) were analysed with an
unpaired, two-sided t test, results of g were analysed with a two-way ANOVA. *pvalue < 0.05, **pvalue < 0.01, ***pvalue < 0.001, ****pvalue < 0.0001.
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this, we interrogated the ZFAND3 neighboring interactome, using
the BioID screening technology27. Briefly, we expressed ZFAND3
fused with a biotin ligase (ZFAND3-BirA) in GSCs, which allowed
the biotinylation of proteins in close proximity (~10 nm) (Fig. 6i).
After streptavidin-based purification, biotinylated proteins were
analysed by mass spectrometry, and statistical analysis revealed
143 significantly enriched proteins in ZFAND3-BirA cells compared
to control (adj. p value < 0.05, FC > 2) (Fig. 6j). Gene ontology
analysis indicated candidate interactors to be involved in RNA
regulation and transcriptional processes (Fig. 6k, Supplementary
Fig. 7c), reinforcing our hypothesis. To validate these results we
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and subsequent mass spectrometry analysis (Supplementary
Fig. 7d–f). Among the 143 proteins identified as ZFAND3 inter-
actome, 22 proteins were also pulled-down by FLAG Co-IP sup-
porting these as ZFAND3 interactors (Fig. 6l). These included
several proteasome-associated proteins (PSMD1, PSMD8, PSMC3),
nuclear importins (KPNA3, KPNA4), and splicing factors (e.g.,
PUF60, SF1, PPIL4) (Supplementary Fig. 7g). Since we found the
invasion-related activity of ZFAND3 to be localized to the nucleus,
we focused on nuclear proteins. Database-driven analysis of protein
complexes (via the Dragon Database for Human Transcription Co-
Factors and Transcription Factor Interacting Proteins (TcoF-DB)28
revealed interacting proteins PUF60, Pontin and Treacle (respec-
tively encoded by PUF60, RUVBL1 and TCOF1 genes) as common
binding partners within a GPN-loop GTPase 1 (GPN1) complex. To
investigate if the interaction with ZFAND3 could be further con-
firmed by western blot, FLAG-tagged ZFAND3 from overexpressing
cells (NI-ZFAND3 OE) was immunoprecipitated and analysed.
PUF60 co-immunoprecipitated with ZFAND3 thereby validating it
as a ZFAND3 interaction partner (Supplementary Fig. 7h), a weak
background detected in control cells was not present when using
isotype-specific IgG control in overexpressing cells. Technical rea-
sons prevented confirmation of direct interaction with TCOF1 or
Pontin by WB Co-IP.
Next, we aimed to relate these findings to events taking place at
the promoter regions of potential target genes. We in-silico
analysed the promoters of COL6A2, NRCAM and FN1 with the
Genomatix tool and identified a multitude of GC-rich target
sequences, preferentially recognized by ZF containing DNA-
binding proteins (Fig. 7a–c). We thus performed dual-luciferase
reporter assays in U87 or HEK293T cells with the promoter
sequences of COL6A2, NRCAM or FN1 and detected an increased
luciferase signal upon ZFAND3 co-expression, demonstrating
that ZFAND3 was able to activate the promoter region of the
genes of interest and induce their transcription (Fig. 7d–f). As
expected the effect was not seen with ZFAND3-Δ1Δ2 (lacking
both ZF domains). We also assessed expression of COL6A2,
NRCAM and FN1 genes in NI GSCs stably expressing ZFAND3
(Supplementary Fig. 8a–d) or ZFAND3 mutant constructs
(Supplementary Fig. 8e–j) with no marked change in expression
of target genes. Although unexpected, the latter might be related
to adaptation to long term overexpression. Finally, we performed
ChIP-qPCR experiments in NI GSCs overexpressing FLAG-
tagged ZFAND3 or FLAG-tag alone. We observed association of
ZFAND3 with in silico predicted ZF consensus sites in the
promoter regions of COL6A2, NRCAM, and FN1 in ZFAND3
overexpressing cells compared to controls (Fig. 7g–i). In line,
point mutations introduced into ZF consensus sites contained
within respective promoter regions failed to comparably induce
luminescence in reporter assays for target genes (Fig. 7d–f). In
summary, we propose that ZFAND3 induces the expression of
invasion-related genes through activation of a transcriptional
complex involving PUF60, ultimately boosting the invasive
behavior of GBM cells (Fig. 7j).
Discussion
ZFAND3 is a member of the ZFAND family of proteins, which
contain a ZF domain of the AN1 type. ZF proteins ensure a
plethora of cellular functions in health and disease, such as DNA
recognition, RNA packaging, transcriptional regulation, and are
involved in many aspects of cancer progression29. In humans,
there are eight ZFAND family members, of which only ZFAND2a
and ZFAND4 have recently been implicated in cancer30–33.
Members of the ZFAND family are associated with stress response
and proteasomal degradation through recruitment of the 26 S
proteasome, e.g., ZFAND134, ZFAND2A/B30,35, ZFAND536, and
ZFAND637. ZFAND3 has so far only been associated to type 2
diabetes susceptibility15, but nothing is known about its cellular
function or its role in tumor biology. Here, we have identified and
validated ZFAND3 as a modulator of GBM cell invasion, and
demonstrate that it acts through regulation of transcriptional
activity. We find that in patient samples ZFAND3 expression is
increased in infiltrative cells from the tumor margin.
At the mechanistic level, we show that ZFAND3-induced
invasion activity relies on its nuclear localization and requires
integral AN1 and A20 ZF domains. The prevention of nuclear
translocation and invasive phenotype through removal of the NLS
signal and rescue of localization and activity by addition of a new
NLS demonstrates that ZFAND3 acts in the nucleus. This is in
contrast to other ZFAND proteins that are primarily located in the
cytoplasm and associated to the ubiquitin-proteasome system
(UPS), which may also explain the differences observed with ZF
domain mutant constructs. While single deletion of either the
AN1 (ZFAND3 Δ1) or the A20 domain (ZFAND3 Δ2) did not
impair nuclear translocation, the invasion phenotype was lost.
This might be explained by a conformational change in the pro-
tein structure, interfering with DNA or protein binding hence
affecting its activity. Functional studies of other members of the
ZFAND protein family employing similar deletions have shown
that proteins with deletion of one of the two domains retain
certain functions. e.g., in ZFAND5 the AN1 domain is required
for the stimulation of peptidase activity whereas the A20 domain
is needed for the binding of polyubiquitinated proteins36 and both
ZFAND5 AN1 and A20 domains were found to be essential for
RNA stabilization38. Also, the AN1 domain and UBL domains of
ZFAND1 were found to be required for its binding to PSMD1 and
p97/Cdc48, respectively34,39. In an attempt to further nail down
Fig. 5 ZFAND3-induced invasion requires nuclear localization and presence of zinc-finger domains. a Structural overview of ZFAND3 protein and
corresponding mutants with zinc finger domain deletions (Δ1, Δ2, Δ1Δ2), mutated nuclear localization signal (mutNLS) and NLS rescue with c-myc NLS
(mutNLS-NLS). HA-tag: hemagglutinin tag. N: N-terminus, C: C-terminus. b Expression of NLS constructs in NI GSCs as confirmed by qPCR (n= 3
biologically independent samples), results were analysed with a two-tailed, unpaired t test, and (c) by Western blot (n= 3). d IF staining showing that
ZFAND3-mutNLS does not translocate to the nucleus, while mutNLS-NLS rescue does (green: HA, blue: DAPI. Scale bars = 10 µm). (n= 2) e Proliferation
assay of cells with indicated constructs control (measurements done at day 3; n= 7 biologically independent experiments for Ctr, ZFAND3 and ZFAND3-
mutNLS, n= 3 biologically independent experiments for ZFAND3-mutNLS-NLS). f, g Boyden chamber invasion assay showing loss of invasion phenotype
with ZFAND3-mutNLS and rescue with ZFAND3-mutNLS-NLS in NI GSC (n= 6 biologically independent experiments for Ctrl, ZFAND3 and ZFAND3-
mutNLS, n= 3 biologically independent experiments for ZFAND3-mutNLS-NLS) (Scale bar = 100 µm). Results were analysed with a two-tailed, unpaired
t test. h Expression of deletion constructs in NI GSCs by qPCR (n= 3 biologically independent samples). Results were analysed with one-way ANOVA (h)
Western blot (i) (n= 3). j Proliferation of cells overexpressing respective constructs (n= 3 biologically independent experiments). Results were
analysed with a two-way ANOVA. k, l Boyden chamber invasion assay indicating loss of invasion induction with deletion constructs (n= 4 biologically
independent experiments) (Scale bar = 100 µm). Results were analysed with one-way ANOVA. m IF staining showing that ZFAND3 Δ1 and ZFAND3 Δ2
mutants localize to the nucleus, whereas ZFAND3 Δ1Δ2 does not (red: ZFAND3, blue: DAPI. Scale bars = 20 µm) (n= 2) All results are displayed as
average ± SEM. *pvalue < 0.05, **pvalue < 0.01, ***pvalue < 0.001, ****pvalue < 0.0001.
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Integrin complex 47.37 7.63E–05
Leukocyte migration 17.2 2.82E–06
Extracellular matrix
organization 15.3 1.34E–08
Cell adhesion 8.49 2.28E–08
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Regulation of nitrogen compound metabolic process
Regulation of cellular metabolic process
Regulation of cellular biosynthetic process
mRNA processing
Transcription initiation from RNA polymerase ll promoter
Regulation of transcription, DNA–templated
Regulation of transcription by RNA polymerase ll
Regulation of gene expression
Nucleobase–containing compound biosynthetic process
Fig. 6 ZFAND3 regulates gene expression and is part of a nucleus-specific protein interactome involved in RNA metabolism, processing, and
transcription. a RNAseq analysis of HI GSCs (n= 3 per condition) identified 58 common DEGs from two KD clones (shZFAND3-1 and shZFAND3-2) vs
shCtrl cells (FDR≤ 0.05, log2FC≤−0.5 and≥ 0.5). b Volcano plot showing DEGs in shZFAND3-2 compared to Ctrl. Among these, 5 downregulated DEGs
were selected for further investigation. c Gene ontology analysis (David database) associated the 58 DEGs to invasion-related GO terms. qPCR confirmed
reduced expression of COL6A2 (d), EGFR (e), FN1 (f), NRCAM (g) and NRP1 (h) in HI GSCs with shZFAND3-1 or shZFAND3-2 compared to shCtrl (n= 3
biologically independent samples). Results are displayed as average ± SEM. Results were analysed with one-way ANOVA. i Bio-ID approach applied to
unveil the interactome of ZFAND3 (adapted from Vernaite et al.59) (n= 4). j Volcano plot showing 143 proteins significantly enriched in ZFAND3-BirA
expressing cells. Two-sample t test was performed with a Benjamini-Hodgberg based FDR < 0.01. k Gene ontology analysis demonstrated that these 143
proteins are involved in RNA metabolism, processing, and transcription. l Co-IP/MS in ZFAND3-FLAG expressing cells confirming 22 proteins from the
Bio-ID experiment as candidate ZFAND3 interactors. Gene names of identified proteins are indicated, with Pontin (RUVBL1), PUF60 (PUF60) and Treacle
(TCOF1) highlighted in bold. *pvalue < 0.05, **pvalue < 0.01.
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the active residues, we introduced missense mutations in the zinc-
complexing amino acids of both domains (constructs M1, M2,
M1-M2) similar to what was reported for ZFAND536. The
equivalent mutation in the A20 domain of ZFAND5 (M1)
abolished its ubiquitin-binding activity36,40, whereas the missense
mutations in the AN1 domain (M2) resulted in a loss of its ability
to stimulate the proteasome36. In our hands ZFAND3 with either
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Fig. 7 ZFAND3 binds to and induces promoter activity on COL6A2, NRCAM and FN1 genes. Transcription factor consensus site analysis (via Genomatix)
identified several putative ZF binding sites (GC-rich regions, hereafter named S1-S13) in the promoter regions of COL6A2 (a), NRCAM (b) and FN1 (c).
Dual-luciferase reporter assays carried out in U87 or HEK293T cells showed that transiently coexpressed ZFAND3 binds to the promoter regions of
COL6A2 (n≥ 5) (d), NRCAM (n≥ 4) (e) and FN1 (n≥ 4) (f) inducing luciferase expression, whereas deletion mutant ZFAND3-Δ1Δ2 did not. Luciferase
activation was compromised on promoters with mutated GC-rich regions (COLA2mut, NRCAMmut, FN1mut) (n≥ 4 biologically independent experiments
*pvalue < 0.05, **pvalue < 0.01, ***pvalue < 0.001, ****pvalue < 0.0001). ZFAND3 binding to GC-rich regions in the promoter regions of COL6A2 (n≥ 3) (g),
NRCAM (n≥ 2) (h) and FN1 (n≥ 4) (i) in HI cells overexpressing ZFAND3 as determined by ChIP qPCR (n≥ 2 biologically independent experiments
*pvalue < 0.05, **pvalue < 0.01, ***pvalue < 0.001, ****pvalue < 0.0001). j Proposed model of ZFAND3 activity in a nuclear protein complex that regulates a gene
expression program to trigger cell invasion.
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its ability to promote invasion (Supplementary Fig. 5b–f), sug-
gesting that these specific residues are not relevant for the
observed nuclear ZFAND3 activity.
In line with its nuclear activity, we identify a nucleus-specific
ZFAND3 interactome, including DNA/RNA binding proteins,
splicing factors and helicases generally involved in RNA meta-
bolic processes and transcription. Based on our proteomics data
and on available database-knowledge, we propose a ZFAND3
containing protein complex including PUF60 (PUF60) and pos-
sibly Pontin (RUVBL1) and Treacle (TCOF1) that regulates gene
transcription (Fig. 7j). Of interest, these three proteins have been
previously involved in cell motility in cancer or during develop-
ment41–43. Binding sites for ZF containing DNA-binding proteins
are enriched in the promoter regions of COL6A2, NRCAM, or
FN1, which were previously described in specific invasive sig-
natures in GBM44,45. We demonstrate binding of ZFAND3 to the
promoter regions of these genes and confirm ZFAND3-induced
transcription by dual-reporter gene assays, indicating a role for
ZFAND3 in a transcriptional invasion program. In analogy to
other ZFAND members, several UPS-associated proteins i.e.,
PSMD1, PSMC3, and PSMD8, were also identified in our
ZFAND3 interactome, which may point to additional cellular
functions in the cytoplasm. In this context, it has been reported
that the UPS plays an essential role in transcription by main-
taining a fine-tuned equilibrium of protein synthesis and degra-
dation46. Whether ZFAND3’s transcriptional activity is linked to
a proteasomal function remains to be determined.
Collectively, these studies identify ZFAND3 as a transcriptional
regulator of invasion-related genes, thereby boosting the infil-
trative phenotype of GBM cells. We show that ZFAND3 requires
nuclear translocation and functional ZF domains for displaying
gene regulatory activity. The specific ZFAND3 interactome points
to a role in transcriptional complex regulation, although an
involvement in proteolysis cannot be excluded. These data
expand our knowledge on the cellular functions and tumorigenic
potential of ZFAND family members thus far largely known for
their role in protein degradation. Further elucidation of the
molecular determinants of ZFAND3 activity in oncogenic path-
ways may provide opportunities for targeting cancers, including
GBM, prone to locoregional invasion or metastasis.
Methods
Cell culture. Patient-derived GSC lines were generated in the laboratories of
Christel Herold-Mende and Rolf Bjerkvig. They were characterized as non invasive
(NI: NCH644; NI-2: GG6), low invasive (LI: NCH421k), and highly invasive (HI:
NCH601; HI-2: NCH465; HI-3: NCH660h and HI-4: BG7) (Fig. 1 and Supple-
mentary Fig. 1). NCH421k, NCH601, NCH465 and NCH660h were cultured as
nonadherent spheres in DMEM-F12 medium (Lonza) containing 1x BIT100
(Provitro), 2 mM Ultraglutamine, 30 U/ml Pen-Strep, 1 U/ml Heparin (Sigma),
20 ng/ml bFGF (Miltenyi, 130-093-841) and 20 ng/ml EGF (Provitro, 1325950500).
NCH644, BG7 and GG6 were grown in Neurobasal base medium (Life Technol-
ogies) supplemented with 1x B27 without vitamine A (Life Technologies) 2mM
L-Glutamine, 30 U/ml Pen-Strep, 1 U/ml heparin, 20 ng/ml bFGF and 20 ng/ml
EGF. Human embryonic kidney 293 (HEK293T) cells and U87 GBM cells were
cultured in DMEM (Lonza) supplemented with 10% fetal bovine serum (FBS),
2 mM Ultraglutamine, and 30 U/ml Pen-Strep. Since GSCs were exposed to 7%
FBS in the Boyden chamber assay, we verified expression of ZFAND3 and stem cell
markers under these conditions (Supplementary Fig. 4f–i). No significant change in
ZFAND3 expression was observed, except for HI cells (NCH601) where expression
was slightly increased. Stem cell markers showed variable expression across cell
lines and in response to FBS, in line with previous reports47 (Supplementary
Fig. 4f–i).
GBM intracranial xenografts in mice. GSCs were implanted in the brain of NOD/
SCID mice (3 mice/group) (Charles River). Mice were anesthetized with a mixture
of ketamine (100 mg/kg) and xylazine (10 mg/kg) and placed in a stereotactic frame
(Narishige Group, Tokyo, Japan). Tumor cells were implanted into the right frontal
cortex using a Hamilton syringe (Hamilton, Reno, NV, USA) (NI, LI, NI ctrl, NI
ZFAND3: 50’000 cells, HI, HI-2, HI shCtrl, HI shZFAND3: 300’000 cells). All
tumor cells were GFP-labeled. Mice were sacrified at defined time points and brains
were extracted and either frozen for cryosections or embedded in paraffin. All
procedures were in accordance with national legislation and the European Direc-
tive on animal experimentation (2010/63/EU) and were approved by the respon-
sible authorities in Luxembourg (protocol: LUPA2017/15).
Invasion assays
In vitro. For Boyden chamber assays, GSCs were plated on transwell chambers
(1500 or 3000 cells/mm 2) (Thincert, Greiner), previously coated with a 1:1 mixture
of 0.05 mg/ml collagen type I (Sigma-Aldrich) and 0.5 mg/ml protein of ECM gel
(Sigma-Aldrich) in 1:1 PBS-DMEM-F12, for 2 h at 37 °C. Medium with 10% FBS
was added as a chemoattractant to the lower chamber. After 3 days, cells were fixed
with 4% PFA and stained with 0.05% crystal violet solution for 15 min. Non-
invading cells were removed, and invasion was evaluated by counting the cells on
the lower side of the membrane under light microscope and ×20 magnification
(5 representative fields per membrane). Experiments were conducted in at least 3
biological replicates (each with 2 technical replicates). To account for the variability
between separate assays, the data are represented as number of invaded cells
relative to the global mean (total number of invading cells) of each experiment,
allowing to combine biological replicates and apply appropriate statistics. The effect
of Boyden chamber conditions on ZFAND3 expression and stem cell markers were
verified by qPCR (Supplementary Fig. 4f–i). For the sprouting assay, 5 × 103 cells/
well were plated in an agar-coated well for 3 days to form a sphere. The sphere was
transferred to an ECM/collagen-coated well, and covered with ECM. Pictures were
taken using EVOS microscope, and invasion was calculated by the ratio of the
sphere area at 48 h to 0 h. Analysis was corrected for the expansion of the
sphere core.
Ex vivo. Brain slices were prepared from adult NOD/SCID mice. Briefly, mice were
sacrificed by cervical dislocation, and brains were rapidly harvested and placed in
ice-cold cutting solution (0.1% GlutaMax, 25 mM HEPES, 50U/ml Pen-Strep in
DMEM). Brain slices (400 μm thick) were generated with a McIlwain Tissue
Chopper and cultured on transwell chambers (1 μm pore size) in a 1:1 mixture of
HibernateTM-A medium (ThermoFisher) supplemented with 20% BIT-100 and
100U/ml Pen-Strep with and DMEM-F12 supplemented with 20% BIT-100, 100U/
ml Pen-Strep, 200 mM ultraglutamine and 1U/ml heparin.
Brain slices were cultured 4 days prior to GSC implantation. For this, 5 × 104
GFP-labeled cells in 1 μl of ECM were injected in the cortex, above the corpus
callosum, by gently punching a hole in the tissue and slowly releasing the cell/gel
mixture. For the quantification of colonized area, pictures were taken every 2–3
days using the EVOS microscope and analysed with ImageJ. After 9 days, live cell
imaging using Incucyte was performed, and the velocity of GFP positive invading
cells in the brain slices were assessed with ImageJ (15 cells per condition and 10
replicates per cell line).
In vivo. For invasion analysis of HI and NI cells in orthotopic xenografts (n= 3),
8 µm cryosections were used. For each xenograft 3 sections were counted (in total 9
per condition). Sections at the level of the injection side were choosen and all GFP
positive HI cells were counted manually in the contralateral hemisphere as shown
in Supplementary Fig. 4j. For invasion analysis of NI cells, all GFP positive NI cells
escaping the tumor mass were manually marked and counted (example shown in
Supplementary Fig. 4k, l). Imaging was performed on a Ni-E microscope (Nikon)
with the NIS Elements Software.
For invasion assays, data were analyzed using the GraphPad Prism 8 software.
Results are reported as mean ± standard error of the mean, and n is described as
the number of biological replicates. Data were analyzed with two-tailed Student t
test. Statistical significance was set at p < 0.05.
Genome-wide shRNA library screen. A lentiviral-based genome-wide shRNA
pooled library contained 95’700 shRNAs targeting 18.205 human genes
(5 shRNAs/gene) (RHS6083, Dharmacon). Loss-of-function screen was performed
in triplicates starting with 4 × 107 HI cells (MOI 0.3, fold representation of shRNAs
100x). After 3 days of puromycin selection (1.5 μg/ml), a reference sample (baseline
control) was collected (2 × 107 cells). Next, 5 × 105 HI cells were plated per
transwell chambers (in total 24 transwell chambers per replicate to ensure 100x
fold representation of shRNAs) (see protocol below) and after 3 days, invasion-
deficient and invasion-competent cells were harvested, genomic DNA was
extracted and shRNA sequencing libraries were prepared by PCR amplification
according to the manufacturers protocol (RHS6083, Dharmacon). Libraries were
pooled and 50 bp single-end sequencing was performed on an Illumina HiSeq 2500
platform (Illumina, Inc). The number of reads per sample were adapted according
to the manufacturers protocol depending on the numbers of cells initially used for
library preparation (per 106 cells, about 107 reads were sequenced). The protocol
followed standard procedures and library representation rules of shRNA pooled
screens9. The comparison of shRNA representation in invasion-deficient and
invasion-competent cells was performed using the combination of four standard
analysis methods: redundant siRNA activity (RSA)19, RNAi gene enrichment
ranking (RIGER)20, Model-based Analysis of Genome-wide CRISPR-Cas9
Knockout21,22 and HiTSelect23. The analysis focused on shRNAs significantly
enriched in invasion-deficient cells. Baseline reference was used to verify shRNA
representation after transduction. Only gene candidates with significant differential
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shRNA representation in all four analysis methods were considered as hits. The
total screen was performed in three independent biological replicates.
Immunohistochemistry on GBM xenografts. Coronal sections (8 μm) from
paraffin-embedded mouse brains were pretreated for 5 min with Proteinase K
(Dako) followed by 20 min incubation at 95 °C in retrieval solution (Dako). The
Dako Envision+ System-HRP was used following the manufacturer’s instructions.
Primary antibodies were incubated for 2 h at RT, and secondary antibodies for 1 h
at RT (list of antibodies in Supplementary Table 3). Signal was developed with 3,3′-
diaminobenzidine (DAB) chromogen in 5–10 min, and pictures were acquired
using a Ni-E microscope (Nikon).
For immunofluorescent staining, cells plated on ECM coated coverslips and
cryosections of orthotopic xenografts were fixed and permeabilized in TBS with
0.1% Triton (TBST), followed by blocking with 10% FBS for 1 h. Primary
antibodies were incubated overnight at 4 °C (list of antibodies in Supplementary
Table 3). Secondary antibodies were applied with DAPI for 1 h at RT. The cells and
cryosections were then washed and mounted with Fluoromount (Sigma). Imaging
was performed on a Ni-E microscope (Nikon) with the NIS Elements Software or
LSM880 confocal microscope (Zeiss) with the Zeiss Zen Software. Data were
analyzed using the GraphPad Prism 8 software. Results are reported as mean ±
standard error of the mean, and n is described as the number of biological
replicates. Data were analyzed with two-tailed Student t tests or ANOVA. Statistical
significance was set at p < 0.05. Immunofluorescent staining for ZFAND3, IBA1
and NeuN was done as described below for clinical samples.
Immunohistochemistry on GBM clinical samples. Human tissue samples for
immunohistochemistry were collected at Odense University Hospital, Odense,
Denmark between 2010 and 2014 with approval from the Danish Data Inspection
Authority (approval number 16/11065) and the Regional Scientific Ethical Com-
mittee of the Region of Southern Denmark (approval number S-20150148). All
samples were diagnosed as GBM according to the 2016 WHO classification.
21 GBM with ≥60% P53-positive cells in central tumor areas and simultaneously
including areas with diffuse tumor cell infiltration and tumor periphery were
subject to double immunofluorescence stainings for P53 and ZFAND3. P53 protein
expression was used to localize tumor cells, and thereby enable measurement of
ZFAND3 protein expression in both tumor cells and nontumor cells throughout
the different tumor regions. Tissue sections of 3 µm were cut on a microtome, and
subject to deparaffinization and heat-induced-epitope retrieval with CC1-buffer
(Ventana Medical Systems). Tissue sections were then stained with primary
ZFAND3 antibody (clone: HPA016755, Atlas antibodies, 1:600 for regular
immunohistochemistry, 1:1000 for immunofluorescence) for 32 minutes on the
Ventana Discovery Ultra platform (Ventana Medical Systems). Antibody detection
was performed with the Optiview-DAB detection system for regular immunohis-
tochemistry and DISCOVERY OmniMap anti-Rb HRP coupled with the DIS-
COVERY Cy5 Kit for immunofluorescence. For double-fluorescence stainings,
tissue sections were subject to a second heat-induced epitope retrieval and then
incubated with either primary P53 antibody (clone: DO7, Ventana Medical Sys-
tems, ready-to-use) for 4 min, Iba1 antibody (Wako Pure Chemical Industries,
1:3000) for 16 minutes or NeuN (clone: A60, Chemicon, 1:500) for 32 min.
Detection was performed with DISCOVERY OmniMap anti-Ms/anti-Rb HRP
coupled with the DISCOVERY FAM Kit. Nuclei were counterstained with DIS-
COVERY QD DAPI and slides mounted with VECTASHIELD mounting medium
without DAPI.
Fluorescence images were acquired with a Leica DM6000B microscope with an
Olympus DP72 camera. Regions of interest including central tumor area, areas
with intermediate tumor infiltration and peripheral tumor areas were manually
outlined for each slide using the Visiopharm software V6.6.1 (Visiopharm,
Hoersholm, Denmark). The software was set to randomly sample 10 images from
each defined region of interest on each slide at 20X magnification. A software based
cell-classifier was programmed to identify P53-positive tumor cells, DAPI-positive
cells and ZFAND3-staining. Finally, the fractions and mean intensities of
ZFAND3-positive tumor- and nontumor cells, including tumor cells stratified by
nuclear/cytoplasmatic ZFAND3 staining were measured by the classifier
(Supplementary Fig. 3a, b). Four tumors did not have ZFAND3 protein expression
and were excluded from data analysis. Comparison of multiple groups was
performed with ANOVA and Tukey´s post-test for data with Gaussian distribution
and Kruskal-Wallis test with Dunn´s post-test for data without Gaussian
distribution. Comparison of two groups was performed with T-tests for data with
Gaussian distribution and Mann Whitney tests for non-Gaussian distributed data.
ZFAND3 constructs. ZFAND3 deletion constructs included deletion of ZF
domain AN1, A20 or both. In the mutant constructs putative Zinc complexing
amino acids (AAs) were mutated to alanine: C32A+C35A (M1); C176A+ C181A
in (M2); all four (M1-M2). For the mutant NLS constructs, the three amino acids
K132, R133 and R135 were mutated to Alanine (wildtype NLS peptide:
SPVKRPRLL, mutNLS peptide: SPVAAPALL). The NLS sequence PAAKRVKLDG
(coding for the c-Myc NLS) was added to the C-terminus of the ZFAND3mutNLS
N-terminal of the HA-tag. Mutant constructs are shown in Supplementary Fig. 5
and listed in Supplementary Table 4. shRNAs against ZFAND3 are shown in
Supplementary Table 2.
All constructs were transduced in different patient-derived GSCs using
lentiviral vectors. Lentiviral particles were produced in HEK cells by co-
transfection of the plasmid of interest with the viral core packaging construct
pCMVdeltaR8.74 and the VSV-G envelope protein vector pMD.G.2 as previously
described48. Supernatant containing viral particles was used to transduce 4 × 105
GSCs and puromycin selection (1 μg/ml) was applied to obtain stably
transduced cells.
Quantitative real-time PCR. 1 μg of total RNA was extracted using Qiagen
RNeasy Mini Kit (Qiagen) and reverse transcribed to cDNA using the iScript
cDNA Synthesis Kit (Bio-Rad) or SuperScriptIII with random primers (Invitro-
gen), according to the manufacturer’s protocol. qPCR was carried out using Fast
SYBR Green Master Mix and the Viia 7 Real Time PCR System (Life Technologies;
Ta= 60 °C). qPCR reaction was performed in 5 μL volume. Fold-change (FC) was
calculated using the ΔCt method and normalized to the expression of EF1α. See
Supplementary Table 1 for the list of primers. CT-values were determinded using
the QuantStudio real time software and data were analyzed using Microsoft Excel
and the GraphPad Prism 8 software. Results are reported as mean ± standard error
of the mean, and n is described as the number of biological replicates. Data were
analyzed with two-tailed Student t tests or ANOVA. Statistical significance was set
at p < 0.05.
Western blot. Total proteins from GSCs with ZFAND3 manipulations were
extracted in RIPA lysis buffer and quantified using Bradford reagent (BioRad).
After SDS-PAGE electrophoresis, proteins were transferred on nitrocellulose
membrane (iBlot, Life Technologies). Primary antibodies were diluted in blocking
solution (milk 5%) and incubated overnight at 4 °C (list of antibodies in Supple-
mentary Table 3). After incubation with HRP-conjugated secondary antibodies, the
chemiluminescent signal was recorded using the Pierce ECL Western blot detection
kit (ThermoFisher), and the ImageQuant LAS4010 imaging station and software
(GE Healthcare) and Image J.
Microarray analysis. Genome-wide expression profiles of NI, LI, and HI were
determined using the GeneChip Human Gene 1.0ST Arrays (Affymetrix), as
described49. Briefly, total RNA was extracted using QIAGEN RNeasy Mini Kit
(Qiagen), processed using the Affymetrix WT Expression kit before being hybri-
dized on Affymetrix GeneChip Human Gene 1.0 ST arrays, according to the
manufacturer’s instructions (protocol P/N 702808 Rev.6). Upon hybridization,
microarrays were washed, stained and scanned according to manufacturer’s stan-
dard procedures. Microarray data are available in the Gene Expression Omnibus
(GEO) repository under accession number GSE134470.
RNA sequencing. For RNA sequencing, total RNA was exctracted from shCtrl,
shZFAND3-1 and shZFAND3-2 highly invasive cells using RNeasy Plus Mini Kit
(Qiagen) according to manufacturer’s protocol. RNA purity was assessed using the
Agilent 2100 Bioanalyzer. 500 ng total RNA with a RIN of at least 9.7 were used for
RNA sequencing. TruSeq library preparation on 9 samples (3 replicates per group)
was performed according to the Illumina standard protocol. Paired end of 2x 75 bp
reads was performed using the NextSeq500 (Illumina). Raw sequencing data was
mapped to human genome (assembly version Genome Reference Consortium
Human build 38, GRCh38) using Bowtie v2-2.3.250. Transcript abundance was
evaluated with HTSeq v0.6.151. The normalization and transcripts differential
expression analyses of count data were performed using the DESeq2 package52.
Comparisons of shZFAND3-1 vs. shCtrl and shZFAND3-2 vs. shCtrl were assessed
with the following parameters: fold change > log2 −0,5 fold, false discovery rate
0.05. Common differentially expressed genes in both comparisons were considered
as hits (Supplementary Table 6). RNAseq data are available in the GEO repository
under accession number GSE138618.
Streptavidin enrichment of biotinylated proteins and on-bead digestion (Bio-
ID). For the analysis of ZFAND3 interactome, NI GBM GSCs (NCH644) were
stably transduced with the myc-BioID-ZFAND3 construct (Supplementary
Table 4), nontransduced cells were used as control. To activate the biotin ligase,
cells were incubated in complete media supplemented with 100 µM D-Biotin (Carl
Roth) for 48 h. After two PBS washes, cell pellets were lysed in 1% sodium
deoxycholate in 50 mM ammonium bicarbonate pH8 and protease inhibitor
cocktail, sonicated, incubated 30 min on ice and centrifuged at 11,000 × g and 4 °C
for 30 min. Supernatant was recovered and proteins were quantified using Pier-
ceTM BCA Protein Assay Kit (Thermo Scientific). PierceTM Streptavidin Magnetic
Beads (Thermo Scientific) were washed once in cold lysis buffer, and 1.8 mg of
protein per sample was incubated with 50 µL of beads for 3 h at 4 °C with gentle
end-over-end rotation. Beads were captured with a magnetic stand, washed 3 times
in cold lysis buffer and 3 times in cold 50 mM ammonium bicarbonate pH8.
Proteins were digested overnight on beads at 37 °C and 60 xg with 1 µg of trypsin
(Promega). Fresh trypsin (0.5 µg) was added to the beads and incubation was
extended for 2 h at 37 °C and 60 xg. Beads were captured with a magnetic stand
and peptides were transferred to a new tube. Beads were rinced twice with 100 µL
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of 50 mM ammonium bicarbonate and these 2 rinses were pooled to the previously
eluted peptides. Samples were further reduced with 10 mM DTT for 45 min at
37 °C and 60 xg, and carbamidomethylated with 25 mM iodoacetamide for 30 min
at RT and 60 xg in the dark. Peptides were finally centrifuged 15 min at 11,000 × g
at 4 °C to remove any insoluble material.
ZFAND3-FLAG Coimmunoprecipitation for mass spectrometry. Co-
Immunoprecipitation (Co-IP) for mass spectrometry (MS) was done on whole cell
lysate using the Dynabeads™ Co-IP Kit (Invitrogen, 14321D). For antibody cou-
pling, 1.5 mg Dynabeads™ M-270 Epoxy were incubated with 8 µg of FLAG M2
antibody (Sigma F1804) at 37 °C on a mixing roller for 16 h. Beads were
washed according to manufacturer’s instructions and diluted to a concentration of
10 mg/ml and left at 4 °C until further processing. NI GBM GSCs overexpressing
ZFAND3 with a FLAG-tag were incubated in complete media supplemented and
while harvesting washed twice in ice-cold PBS. Cells were lysed with 1x IP Buffer
containing NaCl 100 mM, DTT 1 mM and one cOmplete™ EDTA-free Protease
Inhibitor Cocktail for 15 min on ice, and sonicated. The lysates were quantified
using the Bradford Reagent (Bio-Rad). Proteins of interest were captured by
incubating 1 mg of protein lysate with 1.5 mg of antibody-coupled beads at 4 °C for
30 min. Beads were resuspended in cold ammonium bicarbonate 50 mM, reduced
with DTT 10mM for 45 min at 37 °C and 60 xg, and carbamidomethylated with
iodoacetamide 25 mM for 30 min at RT and 60 xg in the dark. Proteins were
digested with 1 μg of trypsin (V5111, Promega) overnight on beads at 37 °C and
60 xg. Fresh trypsin (0.5 μg) was added to the beads and incubation was extended
for 2 h at 37 °C and 60 xg. Dynabeads were captured with a magnetic stand,
peptides were recovered and transferred to a new tube. Beads were rinced twice
with 100 μL of ammonium bicarbonate 50 mM and these 2 rinses were pooled to
the previous eluate. Peptides were centrifuged 15 min at 11,000 × g at 4 °C to
remove any insoluble material, acidified in 1% formic acid, desalted on Sep-Pak
tC18 Elution Plates (Waters, 186002318), dried by vacuum centrifugation and
reconstituted in 12 μL of 1% Acetonitrile/0.05% trifluoroacetic acid. Samples were
quantified by Nanodrop and further analysed by mass spectrometry (see below).
Mass spectrometry analysis and data analysis. Peptides were acidified in 1%
formic acid, desalted on Sep-Pak tC18 µElution Plates (Waters, 186002318), dried
by vacuum centrifugation and reconstituted in 20 µL of 1% Acetonitrile / 0.1%
formic acid. 1 µL of each sample was measured by LC-MS/MS on a Q-Exactive Plus
mass spectrometer (Thermo) connected to a Dionex Ultimate 3000 (Thermo), run
in trap mode using a Acclaim Pepmap 100 trap column (Dionex). The peptides
were separated on a 15 cm Acclaim pepmap RSLC column (Dionex) using a 89 min
gradient (2% to 50% acetonitile) with a flow rate of 0.3 μl/min. MS acquisition was
performed with an MS1 resolution of 70,000 and a scan range from 375 to 1500 m/
z with an AGC target of 3 × 106. The top 12 peaks were selected for fragmentation
in data-dependent mode using an MS2 resolution of 17,500 and a maximum
injection time of 45 ms and an isolation window of 1.2 m/z and an AGC target of
105. Dynamic exclusion was set to 20 s and the normalized collision energy was
specified to 28.
For analysis, the MaxQuant software package version 1.6.5.053 was used.
Carbamidomethylation on cysteine was set as a fixed modification and oxidized
methionine and acetylated N-termini as variable modifications. Peptide tolerance
was 20 ppm and the minimum ratio for LFQ was set to 2. An FDR <1% was
applied for peptides and proteins and the Andromeda search54 was performed
using a human Uniprot database (July 2018). MS intensities were normalized by
the MaxLFQ algorithm implemented in MaxQuant55 while using the match-
between-runs feature.
Only protein groups that were not marked as potential contaminants nor
detected by MaxQuant using reverse database were kept for the analysis. LFQ-
normalized intensities were log2-transformed. Statistical analysis of the dataset was
performed using R-statistical software package (version 3.4.1). For data analysis,
first, proteins that were only identified by site or were potential contaminants were
excluded. Only the proteins that were found in at least three biological replicates
for every condition were used for column wise imputation from a normal
distribution and subsequent statistical analysis. Significantly differentially expressed
protein groups were detected by R-package limma56. For this, a two-sample t test
was performed with a Benjamini-Hodgberg based FDR <0.01. Abundance changes
with a p value < 0.05 and a minimum fold change of 2 were considered significant
(Supplementary Table 7 for BioID experiment, Supplementary Table 8 for IP
experiment). The GO analysis was carried out by R software, p value and q value
cutoff 5%, n and minimum 3 proteins per category as threshold: significantly,
differentially regulated proteins (corresponding Uniprot IDs) were used as targets
and all other proteins captured by proteomics experiment were considered as a
background. Protein IDs that matched several gene IDs were removed from the
analysis.
ZFAND3-FLAG coimmunoprecipitation for western blot analysis. Co-IP with
subsequent Western blot analysis was performed on nuclear extracts following
Agoston and Schulte57. For antibody coupling, 1 mg Dynabeads™ M-270 Epoxy
were incubated with 5 µg of FLAG M2 antibody (Sigma F1804) or Mouse IgG at
37 °C on a mixing roller for 16 h. Fresh nuclear proteins extracts from NI GBM
GSCs overexpressing ZFAND3 with a FLAG-tag and Ctrl-FLAG expressing cells
were prepared as following. 2 × 106 were used to prepare cytoplasmic lysates in
300 µl Buffer A+ (10 mM HEPES, 10 mM KCl, 1 mM DTT, 1x cOmpleteTM
EDTA free), followed by 15 min incubation on ice 30 µl IGEPAL/PBS solution was
added and cells were briefly vortexed. The nuclei were pelleted by centrifugation for
1 min at 9000 × g at 4 °C. Nuclear extract lysis was done by adding 180 µl Buffer
B+ (10 mM HEPES, 10 mM KCL, 1 mM DTT, 400 mM NaCl, 1% IGEPAL, 1x
cOmpleteTM EDTA free) and incubated for 15 min on a rotating wheel. To obtain
isotonic salt concentration 300 µl Buffer A+was added. Lysates were treated with
DNase I (Ambion) with 50U for 30 min at 4 °C. Nuclear protein extracts were pre-
cleared for 2 h using 0,3 mg Dynabeads™ M-270 Epoxy at 4 °C on a rotating wheel.
30 µl of each lysate was kept as input control for later. Dynabeads were equilibrated
in 900 µl Buffer BP+ (3:1.8 ratio of Buffer A and B) before adding the lysates.
Nuclear protein extracts were divided in two (FLAG and IgG) to use equal amount
of lysate per IP. Dynabeads-antibody containing lysates were incubytes for 2 h at
4 °C on a rotating wheel. After magentic sepatation of precipitate and supernatant,
supernatant was removed and kept for later as supernatant control. Dynabeads-
bound precipitates were washed four times with Buffer BP + and once with 1x
LBW 0,1 % Tween-20. After the washing steps, 30 µl 4x LDS (50 mM DTT) was
added to each sample and incubated for 10 min at 70 °C. After magnetic separation,
supernatants were transferred into a fresh tube. Samples were directly loaded on a
SDS-PAGE for Western Blot analysis.
Dual luciferase reporter assay. Plasmids encoding the Firefly Luciferase reporter
gene under the control of the candidate gene promoters, and a Renilla Luciferase
plasmid under the control of an SV-40 Promoter were purchased from Vector-
Builder®. Plasmid DNA was purified using NucleoBond Xtra Midi Kit (Macherey-
Nagel). Reporter cells (U87 or HEK293T) were seeded into 24-well plates at a
density of 7.5 × 104 per well and transfected the next day, using 1.5 µl Lipofecta-
mine 2000 (Thermo Fisher), with the selected Luciferase reporter plasmids
(COL6A2, FN1 and NRCAM) and co-transfected with either empty control,
ZFAND3 or ZFAND3 Δ1Δ2. A Renilla Luciferase Reporter was co-transfected with
a 1:10 ratio of luciferase reporter plasmids as a reference control. Luciferase activity
was recorded 30 h post-transfection using Dual-Glo® Luciferase Assay System
(Promega) according to the manufacturer’s instructions, using ClarioStar plate
reader (BMG LabTech). The ratio of the Firefly:Renilla luminescence was calcu-
lated and normalized to the ratio of the empty control. Data were analyzed using
the GraphPad Prism 8 software. Results are reported as mean ± standard error of
the mean, and n is described as the number of biological replicates. Data were
analyzed by ANOVA. Statistical significance was set at p < 0.05.
Chromatin immunoprecipitation (ChIP) qPCR. ChIP was performed as described
previously58 with the following changes: cells were cross-linked for 30min at 4 °C in
2% PFA made from freshly prepared 18.5% PFA. Chromatin was sheared to a mean
length of 100–500 bp with a Bioruptor UCD-200 in a cold room at 4 °C (Diag-
enode). Immunoprecipitation was performed with the antibodies listed in S3. ChIP
precipitates were assessed by quantitative real-time PCR with the primers listed in
Supplementary Table 1 and PowerUpTM SYBRTM Green master mix reagents
(Thermo Fisher Scientific) on a QuantStudioTM 5 Real-Time PCR detection system
(Thermo Fisher Scientific). Enrichment of the precipitated DNA was determined
relative to the input (1:100) as 100 × 2(Ct adjusted input − Ct immunoprecipitate). Results
are reported as mean ± standard error of the mean, and n is described as the number
of biological replicates. Statistical significance was determined using ANOVA in the
GraphPad Prism 8 software.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data generated or analysed during this study are included in this published article
(and its Supplementary Data files). RNAseq data are available in the GEO repository
under accession number GSE138618; DNA microarray data under accession number
GSE134470.
Raw proteomics data have been deposited in the The MassIVE site repository of the
University of California San Diego (ProteomeXchange consortia) under ftp://massive.
ucsd.edu/MSV000086247/. The constructs generated during the current study are
available from the corresponding author on reasonable request.
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